Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   MYLAN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-23
MYLAN
Dec-18
GLENMARK PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs4873,967-   
Low Rs3492,184-   
Sales per share (Unadj.) Rs460.41,825.4-  
Earnings per share (Unadj.) Rs13.449.6-  
Cash flow per share (Unadj.) Rs35.0391.3-  
Dividends per share (Unadj.) Rs2.500-  
Avg Dividend yield %0.60-  
Book value per share (Unadj.) Rs335.11,974.7-  
Shares outstanding (eoy) m282.17514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.91.7 53.9%   
Avg P/E ratio x31.362.0 50.4%  
P/CF ratio (eoy) x11.97.9 151.8%  
Price / Book Value ratio x1.21.6 80.1%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m117,9531,582,214 7.5%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m27,8100-   
Avg. sales/employee Rs Th026,833.1-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0728.6-  
INCOME DATA
Net Sales Rs m129,901939,158 13.8%  
Other income Rs m3,1680-   
Total revenues Rs m133,069939,158 14.2%   
Gross profit Rs m15,125243,019 6.2%  
Depreciation Rs m6,113175,847 3.5%   
Interest Rs m3,49645,170 7.7%   
Profit before tax Rs m8,68522,002 39.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,911-3,500 -140.3%   
Profit after tax Rs m3,77425,502 14.8%  
Gross profit margin %11.625.9 45.0%  
Effective tax rate %56.5-15.9 -355.4%   
Net profit margin %2.92.7 107.0%  
BALANCE SHEET DATA
Current assets Rs m98,737524,425 18.8%   
Current liabilities Rs m50,455382,364 13.2%   
Net working cap to sales %37.215.1 245.7%  
Current ratio x2.01.4 142.7%  
Inventory Days Days784 8.0%  
Debtors Days Days11593 123.4%  
Net fixed assets Rs m76,920182,181 42.2%   
Share capital Rs m282500 56.4%   
"Free" reserves Rs m94,2810-   
Net worth Rs m94,5631,015,998 9.3%   
Long term debt Rs m38,5211,096,588 3.5%   
Total assets Rs m175,6582,725,301 6.4%  
Interest coverage x3.51.5 234.3%   
Debt to equity ratio x0.41.1 37.7%  
Sales to assets ratio x0.70.3 214.6%   
Return on assets %4.12.6 159.6%  
Return on equity %4.02.5 159.0%  
Return on capital %9.23.2 287.8%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m33,7510-   
CASH FLOW
From Operations Rs m6,254195,157 3.2%  
From Investments Rs m-5,285-100,875 5.2%  
From Financial Activity Rs m-775-90,916 0.9%  
Net Cashflow Rs m3251,617 20.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare GLENMARK PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: JENBURKT PH.  CORAL LAB.  ANG LIFESCIENCES INDIA  GUJ.INJ(KER)  MEDICAMEN BI  



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.